“Lilly’s mission is to make life better for people around the world, and today that requires excellence not just in science but also in technology,” said Diogo Rau, executive vice president and chief information and digital officer at Lilly. “I don’t believe any other company in our industry is doing what we do at this scale. As a 150-year-old medicine company, one of our most powerful assets is decades of data. With purpose-built AI models and AI, we can set a new scientific standard that accelerates innovation to deliver medicines to more patients, faster.”
“The AI industrial revolution will have its most profound impact on medicine, transforming how we understand biology,” said Kimberly Powell, vice president of health care at NVIDIA. “Modern AI factories are becoming the new instrument of science, enabling the shift from trial-and-error discovery to a more intentional design of medicines. With its deep scientific heritage and commitment to innovation, Lilly stands as a global leader at the forefront of this new era of medical discovery.”
“Lilly is shifting from using AI as a tool to embracing it as a scientific collaborator,” said Thomas Fuchs, senior vice president and chief AI officer at Lilly. “By embedding intelligence into every layer of our workflows, we’re opening the door to a new kind of enterprise: one that learns, adapts, and improves with every data point. This isn’t just about speed, but rather interrogating biology at scale, deepening our understanding of disease, and translating that knowledge into meaningful advances for people served by Lilly medicines as well as the broader life sciences ecosystem.”
https://www.shacknews.com/article/146553/nvidia-nvda-eli-lilly-lly-partner